- Home
- ZYME vs PRGS Comparison
ZYME vs PRGS Comparison
Compare ZYME & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | PRGS |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2017 | 1991 |
Fundamental Metrics
Financial Performance| Metric | ZYME | PRGS |
|---|---|---|
| Price | $26.43 | $41.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $32.75 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 589.6K | 446.6K |
| Earning Date | 11-06-2025 | 01-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.09 |
| Revenue | $134,481,000.00 | ★ $940,126,000.00 |
| Revenue This Year | $63.57 | $32.42 |
| Revenue Next Year | $89.45 | $1.44 |
| P/E Ratio | ★ N/A | $39.30 |
| Revenue Growth | ★ 116.21 | 31.41 |
| 52 Week Low | $9.03 | $39.00 |
| 52 Week High | $28.49 | $65.93 |
Technical Indicators
Market Signals| Indicator | ZYME | PRGS |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 35.56 |
| Support Level | $26.10 | $42.23 |
| Resistance Level | $26.91 | $43.96 |
| Average True Range (ATR) | 0.95 | 1.06 |
| MACD | -0.25 | -0.20 |
| Stochastic Oscillator | 49.84 | 11.78 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.